NASDAQ:NAOV

NanoVibronix Competitors

$0.85
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.80
Now: $0.85
$0.87
50-Day Range
$0.85
MA: $1.06
$1.20
52-Week Range
$0.54
Now: $0.85
$3.50
Volume478,365 shs
Average Volume3.85 million shs
Market Capitalization$11.38 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.07

Competitors

NanoVibronix (NASDAQ:NAOV) Vs. ISRG, EW, ALGN, ZBH, STE, and SNN

Should you be buying NAOV stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to NanoVibronix, including Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), STERIS (STE), and Smith & Nephew (SNN).

NanoVibronix (NASDAQ:NAOV) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Insider & Institutional Ownership

7.3% of NanoVibronix shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 19.8% of NanoVibronix shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

NanoVibronix has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for NanoVibronix and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NanoVibronix0000N/A
Intuitive Surgical381102.36

Intuitive Surgical has a consensus target price of $750.9444, suggesting a potential downside of 7.58%. Given Intuitive Surgical's higher possible upside, analysts plainly believe Intuitive Surgical is more favorable than NanoVibronix.

Profitability

This table compares NanoVibronix and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanoVibronix-727.90%-418.55%-218.34%
Intuitive Surgical24.45%12.08%10.44%

Valuation & Earnings

This table compares NanoVibronix and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanoVibronix$530,000.0021.48$-5,790,000.00($0.83)-1.02
Intuitive Surgical$4.48 billion21.48$1.38 billion$9.9581.67

Intuitive Surgical has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats NanoVibronix on 11 of the 13 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and NanoVibronix (NASDAQ:NAOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Institutional & Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 7.3% of NanoVibronix shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 19.8% of NanoVibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Edwards Lifesciences and NanoVibronix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences261302.52
NanoVibronix0000N/A

Edwards Lifesciences presently has a consensus target price of $91.1569, suggesting a potential upside of 2.40%. Given Edwards Lifesciences' higher possible upside, equities analysts plainly believe Edwards Lifesciences is more favorable than NanoVibronix.

Profitability

This table compares Edwards Lifesciences and NanoVibronix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
NanoVibronix-727.90%-418.55%-218.34%

Valuation and Earnings

This table compares Edwards Lifesciences and NanoVibronix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.74$1.05 billion$1.8647.86
NanoVibronix$530,000.0021.48$-5,790,000.00($0.83)-1.02

Edwards Lifesciences has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats NanoVibronix on 11 of the 13 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and NanoVibronix (NASDAQ:NAOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Institutional & Insider Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 7.3% of NanoVibronix shares are held by institutional investors. 1.2% of Align Technology shares are held by insiders. Comparatively, 19.8% of NanoVibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Align Technology has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Align Technology and NanoVibronix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology13902.62
NanoVibronix0000N/A

Align Technology presently has a consensus target price of $502.1667, suggesting a potential downside of 17.18%. Given Align Technology's higher possible upside, equities analysts plainly believe Align Technology is more favorable than NanoVibronix.

Profitability

This table compares Align Technology and NanoVibronix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
NanoVibronix-727.90%-418.55%-218.34%

Valuation and Earnings

This table compares Align Technology and NanoVibronix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion19.94$442.78 million$4.96122.24
NanoVibronix$530,000.0021.48$-5,790,000.00($0.83)-1.02

Align Technology has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats NanoVibronix on 11 of the 13 factors compared between the two stocks.

Zimmer Biomet (NYSE:ZBH) and NanoVibronix (NASDAQ:NAOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are held by institutional investors. Comparatively, 7.3% of NanoVibronix shares are held by institutional investors. 0.4% of Zimmer Biomet shares are held by insiders. Comparatively, 19.8% of NanoVibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Zimmer Biomet and NanoVibronix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zimmer Biomet131632.91
NanoVibronix0000N/A

Zimmer Biomet presently has a consensus target price of $167.8636, suggesting a potential downside of 2.34%. Given Zimmer Biomet's higher possible upside, equities analysts plainly believe Zimmer Biomet is more favorable than NanoVibronix.

Profitability

This table compares Zimmer Biomet and NanoVibronix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zimmer Biomet0.52%10.07%4.93%
NanoVibronix-727.90%-418.55%-218.34%

Valuation and Earnings

This table compares Zimmer Biomet and NanoVibronix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.98 billion4.49$1.13 billion$7.8721.84
NanoVibronix$530,000.0021.48$-5,790,000.00($0.83)-1.02

Zimmer Biomet has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats NanoVibronix on 12 of the 14 factors compared between the two stocks.

STERIS (NYSE:STE) and NanoVibronix (NASDAQ:NAOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Institutional & Insider Ownership

90.0% of STERIS shares are held by institutional investors. Comparatively, 7.3% of NanoVibronix shares are held by institutional investors. 1.2% of STERIS shares are held by insiders. Comparatively, 19.8% of NanoVibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

STERIS has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for STERIS and NanoVibronix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STERIS02302.60
NanoVibronix0000N/A

STERIS presently has a consensus target price of $214.25, suggesting a potential upside of 2.94%. Given STERIS's higher possible upside, equities analysts plainly believe STERIS is more favorable than NanoVibronix.

Profitability

This table compares STERIS and NanoVibronix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STERIS13.97%14.44%9.32%
NanoVibronix-727.90%-418.55%-218.34%

Valuation and Earnings

This table compares STERIS and NanoVibronix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$3.03 billion5.86$407.61 million$5.6436.90
NanoVibronix$530,000.0021.48$-5,790,000.00($0.83)-1.02

STERIS has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Summary

STERIS beats NanoVibronix on 11 of the 13 factors compared between the two stocks.

Smith & Nephew (NYSE:SNN) and NanoVibronix (NASDAQ:NAOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Smith & Nephew and NanoVibronix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Smith & Nephew24602.33
NanoVibronix0000N/A

Smith & Nephew presently has a consensus target price of $47.1667, suggesting a potential upside of 16.75%. Given Smith & Nephew's higher possible upside, equities analysts plainly believe Smith & Nephew is more favorable than NanoVibronix.

Profitability

This table compares Smith & Nephew and NanoVibronix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Smith & NephewN/AN/AN/A
NanoVibronix-727.90%-418.55%-218.34%

Institutional & Insider Ownership

8.9% of Smith & Nephew shares are held by institutional investors. Comparatively, 7.3% of NanoVibronix shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Comparatively, 19.8% of NanoVibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Smith & Nephew has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.07, meaning that its share price is 107% less volatile than the S&P 500.

Valuation and Earnings

This table compares Smith & Nephew and NanoVibronix's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew$5.14 billion3.46$600 million$2.0419.80
NanoVibronix$530,000.0021.48$-5,790,000.00($0.83)-1.02

Smith & Nephew has higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Summary

Smith & Nephew beats NanoVibronix on 11 of the 13 factors compared between the two stocks.


NanoVibronix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$812.57flat$96.19 billion$4.48 billion92.55Upcoming Earnings
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$89.02flat$55.37 billion$4.35 billion71.22Upcoming Earnings
Analyst Report
High Trading Volume
Align Technology logo
ALGN
Align Technology
1.9$606.33flat$47.98 billion$2.41 billion27.59Analyst Report
Analyst Revision
News Coverage
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$171.88flat$35.81 billion$7.98 billion1,074.32Analyst Upgrade
Analyst Revision
STERIS logo
STE
STERIS
2.1$208.14flat$17.77 billion$3.03 billion42.22Analyst Downgrade
Increase in Short Interest
Smith & Nephew logo
SNN
Smith & Nephew
2.1$40.40flat$17.75 billion$5.14 billion19.80Unusual Options Activity
Analyst Revision
News Coverage
MSA Safety logo
MSA
MSA Safety
2.1$155.63flat$6.08 billion$1.40 billion44.09
Avanos Medical logo
AVNS
Avanos Medical
1.5$44.98flat$2.16 billion$697.60 million155.10Gap Down
Eargo logo
EAR
Eargo
1.0$47.01flat$1.80 billionN/A0.00High Trading Volume
Increase in Short Interest
Lockup Expiration
Establishment Labs logo
ESTA
Establishment Labs
1.2$69.19flat$1.63 billion$89.57 million-40.94Decrease in Short Interest
Inogen logo
INGN
Inogen
1.2$65.73flat$1.47 billion$361.94 million-730.25Insider Selling
Analyst Revision
News Coverage
Sientra logo
SIEN
Sientra
1.6$7.07flat$404.92 million$83.70 million-3.97Analyst Upgrade
Increase in Short Interest
Invacare logo
IVC
Invacare
1.6$8.79flat$302.59 million$927.96 million-7.15Analyst Downgrade
SMTI
Sanara MedTech
0.8$30.25flat$230.41 million$11.77 million-23.45Decrease in Short Interest
Gap Down
Lakeland Industries logo
LAKE
Lakeland Industries
1.8$27.36flat$219.43 million$107.81 million7.77Earnings Announcement
Analyst Report
News Coverage
Gap Down
Surgalign logo
SRGA
Surgalign
1.7$1.89flat$208.41 million$308.38 million-1.05Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.89flat$208.41 million$308.38 million-1.05Increase in Short Interest
Conformis logo
CFMS
Conformis
1.3$0.85flat$154.50 million$77.43 million-2.49Gap Up
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.84flat$84.81 million$4.87 million-1.46Decrease in Short Interest
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$14.45flat$81.93 million$2.32 million-7.23Analyst Downgrade
Decrease in Short Interest
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.08flat$52.70 million$1.41 million-0.17News Coverage
Gap Down
AHPI
Allied Healthcare Products
0.5$4.48flat$17.97 million$31.89 million0.00
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.